Drug Discovery

#AI #AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Pharma #Technology

Exclusive interview: BenevolentAI on the future of AI

In what BenevolentAI considers a move that deepens its drug discovery and development expertise on its board, Dr John Orloff has been appointed as a Non-Executive Director. Dr Orloff joins the BenevolentAI board as it advances plans to scale its AI platform, partnerships and drug portfolio. DDW’s Megan Thomas speaks… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#Drug development #Drug discovery #Microbiome #Podcast #Precision medicine

Podcast: Opportunities to improve drug discovery systems

This is the latest episode of the free DDW podcast: “Opportunities to improve drug discovery systems”. It covers two articles written for Volume 22, Issue 1 – Winter 2020/21 of the Drug Discovery World Magazine.   The first article is titled “Precision control of protein release… Read More

#News #Trending News

#Biopharmaceutical #Drug development #Events #Webinar

Webinar: Addressing analytical challenges in biosimilar development 

The route to market for biosimilars places strong emphasis on characterisation tools for establishing comparability between biosimilar and innovator products.   Addressing analytical challenges in fast-forwarding biosimilar development processes requires Implementing sophisticated analytical instruments with advanced technologies. The ICH Q6B, cited by both EMA and FDA, highlights electrophoretic data as… Read More

#News

#Collaboration #Drug development #Drug discovery #Gene mutation #Research #Schizophrenia

This week in drug discovery (13-17 September) 

News round-up by DDW’s Megan Thomas for 13-17 September  The news in the drug discovery industry this week has demonstrated the potential that remains untapped for a number of industries at large as well as taking early steps towards future cures and treatments. DDW’s Megan Thomas has… Read More

#News #Trending News

#CRISPR #Drug development #Drug discovery #Gene editing #R&D

Benchling launch cloud solution at virtual event  

Benchling, the biotechnology cloud R&D platform used by organisations including Regeneron, Gilead and Pfizer, hosted a virtual event on September 14 at 8 am PT / 11 am ET called Drive Innovation from Discovery to Development, where the company announced its entry into the Early Development market, launching new solutions that… Read More

#News

#Drug development #Novel therapeutics

Breakthrough Therapy Designation granted in China for lymphoma drug 

Hutchmed has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) for amdizalisib (HMPL-689), a highly selective and potent PI3Kδ inhibitor, for the treatment of relapsed or refractory follicular lymphoma (FL), a subtype of non-Hodgkin’s lymphoma (NHL).  Drug candidates with… Read More

#News #Trending News

#Biosciences #CRO #Drug development #Immuno-oncology #Oncology

High demand for preclinical expertise fuels growth for Nottingham CRO 

Nottingham, UK-based contract research organisation (CRO) Cellomatics Biosciences has reported year-on-year organic revenue growth of 30% since its inception in 2015, as demand for its preclinical and early discovery phase laboratory services and expertise continues to increase.   Based at BioCity Nottingham, Cellomatics is a specialist preclinical CRO with expertise in five main therapeutic areas: oncology,… Read More

#News

#Collaboration #Drug discovery #Mass spectrometry / NMR #Parkinson's #Research #Schizophrenia #Therapeutics

This week in drug discovery (6-10 September) 

News round-up by DDW’s Megan Thomas for 6 – 10 September  DDW’s Megan Thomas selects five stories which showcase results, data, partnerships and research which offer a promising future for both drug development and eventual treatment of a number of diseases.   New potential therapy for… Read More

#News #Trending News

Covid-19
#Clinical trials #Covid-19 #Drug development #Oncology #Therapeutics

Oncology treatment tested in patients with moderate Covid-19 disease 

Australian clinical-stage drug development company Noxopharm has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil (Veyonda), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with moderate Covid-19 disease. Veyonda currently has two main drug actions – a moderating… Read More

#Covid-19 #News #Trending News

#AI #AI / data analytics / healthtech / informatics #Collaboration #Drug discovery #Molecular Biology

IBM Research and Arctoris accelerate closed loop drug discovery 

IBM Research and Arctoris are investigating the application of AI and automation to accelerate closed loop molecule discovery.   IBM Research has developed RXN for Chemistry, an online platform leveraging Natural Language Processing (NLP) architectures to automate synthetic chemistry. Representing chemical reactions via SMILES (Simplified Molecular Input Line Entry System),… Read More

#News #Trending News

#Drug development #Drug discovery #GlobalData #Novel therapeutics

PD market to reach $1.95 billion in 2030 driven by novel therapies

An upcoming influx of new therapies into the Pompe disease (PD) pipeline in the next decade is expected by GlobalData to provide a significant boost to the treatment market for this inherited, and often fatal, disorder that can greatly damage the heart and skeletal muscles. In fact, the market is expected… Read More

#News #Trends & Analysis

#Clinical trials #Drug development #FDA

FDA grant ODD for hyperammonemia in inborn errors of metabolism

Versantis’ lead product candidate VS-01 has been has granted orphan drug designation (ODD) by the Food and Drug Administration (FDA) for the treatment of hyperammonemia (HA) in inborn errors of metabolism (IEM).   “This orphan drug designation from the FDA validates the scientific rationale of VS-01 in a… Read More

#News

Seed funding
#Clinical trials #Covid-19 #Drug discovery #Funding #Research #Therapeutics

ILC Therapeutics completes £3.5 million funding round 

ILC Therapeutics has completed a £3.5 million pre-IPO funding round. Investors include Robert Kopple, Eos Angel Investment Syndicate, Scottish Enterprise and ILCT management.  Chairman Peter Bains said: “With this funding in place, ILCT is now well positioned to strengthen its novel technology platform and to advance its… Read More

#Business & Investment #News

#Clinical trial #Drug development #Drug discovery #Drug targets

Data shows promise for patients with asthma and comorbid nasal polyps 

New data from the Navigator Phase III trial showed that AstraZeneca and Amgen’s tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps.1   Tezepelumab is a potential first-in-class treatment that acts by targeting thymic stromal lymphopoietin (TSLP), an… Read More

#News

#Drug development #Neurodegenerative disorders #Neuroscience #Parkinson's #Pharmaceuticals

Partnership for commercialisation of Parkinson’s drug in Europe 

BIAL has entered into an agreement with Sunovion Pharmaceuticals whereby BIAL received exclusive commercial license rights to commercialise apomorphine sublingual film in the European Union (EU), the European Economic Area (EEA) and the United Kingdom.  Apomorphine sublingual film (APL-130277) is a novel thin film formulation of apomorphine that dissolves… Read More

#News